Bpifrance Large Venture
VC Fund
Bpifrance Large Venture is a VC fund focused on Biotechnology and Food and Beverage. Bpifrance Large Venture operates as an investment firm.
- Total investments:
- 12
- Last investment:
- Lead investor:
- 25%
Last updated:
For AI agents: llms.txt
Industries Bpifrance Large Venture invests in
Stages Bpifrance Large Venture invests in
Countries Bpifrance Large Venture invests in
Investment Focus
Industry
- Biotechnology 5 (42%)
- Food and Beverage 2 (17%)
- Artificial Intelligence 2 (17%)
- Apps 1 (8%)
- Coupons 1 (8%)
Stage
- Series B 3 (25%)
- Seed 2 (17%)
- Series A 2 (17%)
- Series C 2 (17%)
- Pre-Seed 1 (8%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
AFYREN
|
AFYREN develop innovation in biotechnologies for the valorization of non-food biomass and in respect of the environment. | $26.8M / Post-IPO Equity / Oct 28, 2025 | |
La Fourche
|
At La Fourche we believe healthy consumption should be affordable to everyone and our mission is to offer everyday organic products to "the 99%". Based on a a subscription model, our platform offers thousands of organic products with up to 50% discount and allows families to reduce up their spending up to 1000€. Join us! | $37.4M / Series C / Sep 16, 2025 | |
FAIRMAT
|
We are bringing a new, sustainable and innovative way to recycle carbon fiber composite. Thanks to our proprietary technology, we produce a recycled material with a negative footprint! It's a light and strong high-tech material designed to be used in industries such as design, mobility, electronics, construction, transport, and logistics. | $28.9M / Series B / Apr 02, 2025 | |
Bioptimus
|
Bioptimus is a developer of a universal AI foundation model that connects biology at all sizes, from molecules to cells, tissues, and entire organisms. The company's technology turns multiscale data into actionable representations, allowing clients to spark breakthrough discoveries and expedite biomedical innovation. | $41M / Series A / Jan 14, 2025 | |
AQEMIA
|
AQEMIA is a pharmatech company developing a drug discovery platform to discover new drugs for specific therapeutic targets. Its platform combines quantum-inspired physics and machine learning to scale the drug discovery process, generating a growing pipeline of new drug candidates. The company utilizes advanced techniques, including generative AIand atomic scale physics, to design novel drugs tailored for specific therapeutic targets. | $38M / Series A / Dec 10, 2024 | |
Fasst
|
Fasst is involved in the creation, distribution, consulting, and connection of unique digital insurance solutions for brokers and insurers. | $28.4M / Series B / Nov 14, 2024 | |
Storio Energy
|
Storio Energy is an AI-powered energy efficiency technology platform that provides renewable energy. | $5.4M / Seed / Oct 15, 2024 | |
Calyxia
|
Calyxia design and produce microcapsules. Their microcapsules are size controlled from one micron to 50 microns. They completely protect an active ingredient from all damaging processes, and, they release the ingredient at just the right time and place for performance.The result is environmentally cleaner, higher performing formulationchemistry. | $35M / Series B / Sep 05, 2024 | |
Edonia
|
Edonia offers plant-based protein food production with low processed & micro-algae-based ingredients. | $2.1M / Pre-Seed / Apr 24, 2024 | |
ENYO Pharma
|
ENYO Pharma is a biopharmaceutical company incorporated in Jan, 2014, by four scientists of the Infectiology Research Center in Lyon, France, and three seeding partners (2 privates and 1 public).The company is based in the Infectiology Center of Lyonbiopôle in Lyon, France and maintains tight collaborations with the seminal Inserm team and theBSL4 laboratory Inserm-Jean Mérieux.ENYO Pharma has licensed several Inserm patents issued from the discoveries of the founding scientists and developed a unique platform for the identification of intracellular therapeutic targets and molecules.The company is developing treatments against the most important viruses and is thriving to become a global leader in anti-virals. Research and Development is currently focused on human infecting viruses, with the first two programs being dedicated to the treatment of severe and seasonal flu and chronic hepatitis B. The company plans to conduct its molecules to Phase II clinical trials. | $42.6M / Series C / Jan 03, 2024 | |
| See all 12 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Bpifrance Large Venture invest in?
Bpifrance Large Venture invests primarily in Biotechnology, Food and Beverage and Artificial Intelligence startups, most often at Series B and Seed stage. Most of the 12 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Bpifrance Large Venture last invest?
The most recent investment recorded for Bpifrance Large Venture closed in Oct 2025. Shizune tracks 12 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
